From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
LDLR Human Pre-designed siRNA Set A contains three designed siRNAs for LDLR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ldlr Rat Pre-designed siRNA Set A contains three designed siRNAs for Ldlr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ldlr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ldlr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Dim16 is a dual PCSK9/HMG-CoAR inhibitor, with an IC50 value of 19 nM for PCSK9. Dim16 inhibits PCSK9-LDLR binding with an IC50 value of 0.8 nM. Dim16 increases LDL uptake in HepG2 cells .
BRD8518 is a PCSK9 inhibitor (EC50=0.23 μM). BRD8518 lowers blood lipids by upregulating LDLR expression and stimulating LDL uptake. BRD8518 can be used in the study of cardiovascular diseases .
PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .
DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia .
PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .
MeIm (compound 7) is a high-affinity PCSK9 targeting peptide mimetic with cholesterol-lowering activity. MeIm increases cellular uptake of LDL (EC50=6.04 μM) by inhibiting the binding of PCSK9 to LDLR (IC50=11.2 μM). MeIm can be used in the study of cardiovascular diseases .
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
AZD0780 (PCSK9-IN-12) is an orall active PCSK9 inhibitor. PCSK9-IN-12 has bind affinity for PCSK9 with a Kd value of <200 nM. AZD0780 binds to a pocket in the PCSK9 C-terminal domain and does not affect the PCSK9-LDL receptor (LDLR) interaction. AZD0780 inhibits lysosomal trafficking of PSCK9-LDLR complexes and prevents PCSK9-induced LDLR degradation. PCSK9-IN-12 can be used for the research of hypercholesterolemia .
Pseurotin A is a secondary metabolite of Aspergillus and other fungi. Pseurotin A is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC50 = 3.6 μM). Pseurotin A inhibits the PCSK9-LDLr interaction. Pseurotin A shows dose-dependent reduction of PCSK9, along with increased LDLR levels in hormone-dependent breast cancer cell lines. Pseurotin A exhibits antitumor activity .
E28362 is a novel small molecule PCSK9 inhibitor. E28362 blocks the interaction between PCSK9 and LDLR, thereby preventing the degradation of LDLR and maintaining cholesterol homeostasia. E28362 is a promising lead compound for the study of hyperlipidemia and atherosclerosis .
VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
LY 295427 is a LDL receptor modulator and a hypocholesterolemic agent. LY 295427 derepresses the transcription of the LDLR (LDL Receptor). LY 295427 can be used for hypercholesterolemia research .
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development .
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%) .
VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research .
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .
PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .
Acetoacetic acid (lithium) (Standard) is the analytical standard of Acetoacetic acid (lithium). This product is intended for research and analytical applications. Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .
2-(Aminomethyl)phenol (2-Hydroxybenzylamine) is a selective dicarbonyl scavenger. 2-(Aminomethyl)phenol is an antioxidant and scavanger of free radicals and isolevuglandins (IsoLGs). 2-(Aminomethyl)phenol can prevent early recurrence of atrial fibrillation. 2-(Aminomethyl)phenol can reduce inflammation and plaque apoptotic cells and promote efferocytosis and features of stable plaques. 2-(Aminomethyl)phenol can reduce malondialdehyde (MDA)-LDL and MDA-HDL levels in Ldlr-/- mouse model. 2-(Aminomethyl)phenol can be studied in the research of inflammation and cardiovascular disease, such as atherosclerosis, early recurrence of atrial fibrillation (AF) and arrhythmias .
KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .
VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .
VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .
2-(Aminomethyl)phenol (2-Hydroxybenzylamine) is a selective dicarbonyl scavenger. 2-(Aminomethyl)phenol is an antioxidant and scavanger of free radicals and isolevuglandins (IsoLGs). 2-(Aminomethyl)phenol can prevent early recurrence of atrial fibrillation. 2-(Aminomethyl)phenol can reduce inflammation and plaque apoptotic cells and promote efferocytosis and features of stable plaques. 2-(Aminomethyl)phenol can reduce malondialdehyde (MDA)-LDL and MDA-HDL levels in Ldlr-/- mouse model. 2-(Aminomethyl)phenol can be studied in the research of inflammation and cardiovascular disease, such as atherosclerosis, early recurrence of atrial fibrillation (AF) and arrhythmias .
Pseurotin A is a secondary metabolite of Aspergillus and other fungi. Pseurotin A is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC50 = 3.6 μM). Pseurotin A inhibits the PCSK9-LDLr interaction. Pseurotin A shows dose-dependent reduction of PCSK9, along with increased LDLR levels in hormone-dependent breast cancer cell lines. Pseurotin A exhibits antitumor activity .
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .
Acetoacetic acid (lithium) (Standard) is the analytical standard of Acetoacetic acid (lithium). This product is intended for research and analytical applications. Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .
LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-6*His labeled tag.
LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag.
The MESDC2 protein acts as a chaperone and plays a specific role in promoting the folding of the β-propeller/EGF module within the low-density lipoprotein receptor (LDLR) family.In addition to participating in LDLR folding, MESDC2 acts as an important regulator of the Wnt pathway by chaperoning the coreceptors LRP5 and LRP6 to the plasma membrane, thereby affecting Wnt signaling.MESDC2 Protein, Human (HEK293, His) is the recombinant human-derived MESDC2 protein, expressed by HEK293 , with C-His labeled tag.
LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag and A23V, C27G mutation.
LDLR Protein binds LDL, transporting cholesterol via endocytosis. Clustering in clathrin-coated pits initiates internalization. Interactions include DAB2 (via PID domain) through the NPXY motif, hindered by tyrosine phosphorylation. LDLR also interacts with LDLRAP1 (via PID domain) through the NPXY motif, ARRB1, SNX17, and the full-length immature PCSK9 through the C-terminus. LDLR Protein, Rabbit (HEK293, Fc) is the recombinant Rabbit-derived LDLR protein, expressed by HEK293 , with C-hFc labeled tag. The total length of LDLR Protein, Rabbit (HEK293, Fc) is 757 a.a., with molecular weight of 120-140 kDa.
LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293) is the recombinant human-derived LDLR protein, expressed by HEK293, with tag free.
LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LDLR protein, expressed by HEK293 , with C-His labeled tag.
LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, Fc) is the recombinant human-derived LDLR protein, expressed by HEK293, with C-hFc labeled tag.
LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
LDLR Antibody is an unconjugated, approximately 92 kDa, rabbit-derived, anti-LDLR monoclonal antibody. LDLR Antibody can be used for: WB, IHC-P expriments in human, mouse background without labeling.
SORL1; C11orf32; Sortilin-related receptor; Low-density lipoprotein receptor relative with 11 ligand-binding repeats; LDLR relative with 11 ligand-binding repeats; LR11; SorLA-1; Sorting protein-related receptor containing LDLR class A repe
WB, IHC-P
Human, Mouse, Rat
SorLA Antibody (YA2310) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2310), targeting SorLA, with a predicted molecular weight of 248 kDa (observed band size: 270 kDa). SorLA Antibody (YA2310) can be used for WB, IHC-P experiment in human, mouse, rat background.
SORL1; C11orf32; Sortilin-related receptor; Low-density lipoprotein receptor relative with 11 ligand-binding repeats; LDLR relative with 11 ligand-binding repeats; LR11; SorLA-1; Sorting protein-related receptor containing LDLR class A repe
WB, IHC-P, ICC/IF, ELISA
Human
SorLA Antibody (YA5066) is a mouse-derived and non-conjugated monoclonal antibody, targeting to SorLA. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.
LDLR Human Pre-designed siRNA Set A contains three designed siRNAs for LDLR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ldlr Rat Pre-designed siRNA Set A contains three designed siRNAs for Ldlr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Ldlr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ldlr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
